Du Yan, Gong Jiannan, Tian Xinrui, Yan Xiaomei, Guo Tao, Huang Min, Zhang Bingtai, Hu Xiaoyun, Liu Hui, Wang Yinping, Li Jianqiang, Li Maolan
Department of Respiratory Medicine, Shanxi Medical University Second Hospital, Taiyuan, People's Republic of China.
Department of General Surgery, Shanxi Medical University Second Hospital, Taiyuan, People's Republic of China.
Tumour Biol. 2015 Sep;36(10):7473-82. doi: 10.1007/s13277-015-3439-6. Epub 2015 Apr 25.
Japonicone A, which is a natural product isolated from the aerial part of Inula japonica Thunb., has a wide range of clinical applications, including anti-inflammation and anti-oxidation. This study investigated the effects of japonicone A on the growth of non-small cell lung cancer (NSCLC) cell lines. The results showed that japonicone A significantly inhibited the growth of NSCLC cell lines in a dose- and time-dependent manner. This product also blocked cell cycle progression at S phase and induced mitochondrial-related apoptosis by upregulating Bax, cleaved caspase-9, cleaved caspase-3, and cleaved poly(ADP-ribose) polymerase (PARP) protein levels and by downregulating Bcl-2, cyclin D1, CDC25A, and CDK2 protein levels. In vivo, japonicone A suppressed tumor growth via the same mechanism as that observed in vitro. In conclusion, our study is the first to report that japonicone A has an inhibitory effect on the growth of NSCLC cells, indicating that japonicone A administration is a potential therapeutic approach for future NSCLC treatments.
紫菀酮A是从旋覆花地上部分分离得到的一种天然产物，具有广泛的临床应用，包括抗炎和抗氧化作用。本研究调查了紫菀酮A对非小细胞肺癌（NSCLC）细胞系生长的影响。结果表明，紫菀酮A以剂量和时间依赖性方式显著抑制NSCLC细胞系的生长。该产物还通过上调Bax、裂解的caspase-9、裂解的caspase-3和裂解的聚（ADP-核糖）聚合酶（PARP）蛋白水平以及下调Bcl-2、细胞周期蛋白D1、细胞周期蛋白依赖性激酶25A（CDC25A）和细胞周期蛋白依赖性激酶2（CDK2）蛋白水平，阻断细胞周期在S期的进程并诱导线粒体相关凋亡。在体内，紫菀酮A通过与体外观察到的相同机制抑制肿瘤生长。总之，我们的研究首次报道紫菀酮A对NSCLC细胞的生长具有抑制作用，表明给予紫菀酮A是未来NSCLC治疗的一种潜在治疗方法。
